by British National Formulary

The British National Formulary (BNF) provides up-to-date, practical guidance on prescribing, dispensing, and administering medicines. This essential reference reflects current best practice as well as legal and professional guidelines relating to the uses of medicines. BNF 70 (September 2015) has been revised and revalidated to reflect changes in product availability, emerging safety concerns and shifts in clinical practice. Access to the latest edition of the BNF is vital for healthcare professionals, as there are a large number of updates from one edition to the next. To make it even easier to find the information you need, the content in the new BNF 70 has been restructured. You'll find improved consistency and clarity in the print version. See www.bnf.org to find out more, along with sample pages and a clear guide on how to use the improved BNF. Some of the significant content updates in this edition include: - New safety information about reducing the risk of QT interval prolongation and Torsade de Pointes with hydroxyzine - New advice about the risk of lymphopenia and potential risk of progressive multifocal leukoencephalopathy with dimethyl fumarate - Further guidance on the restricted use of codeine for the treatment of cough and cold symptoms in children - Addition of new indications for omalizumab for treating chronic spontaneous urticaria and for lenalidomide in certain patients with multiple myeloma - Updated dosing information for the use of tramadol in the treatment of acute and chronic pain - Guidance about dose reduction for lisdexamfetamine mesilate for patients with severe renal impairment - Updated contra-indications for aceclofenac in patients with certain established cardiovascular diseases - Addition of new preparations, including DuoResp Spiromaxr (budesonide with formoterol), Envarsusr (tacrolimus), Fostair NEXThalerr (beclometasone with formoterol), Jaydessr (levonorgestrel), Ketoconazole HRAr (ketoconazole) and L

Product Details